OR WAIT null SECS
September 26, 2023
Under a new pact, Genentech and PeptiDream will collaborate to discover and develop novel peptide-radioisotope drug conjugates.
September 21, 2023
The AstraZeneca rare disease group hopes to use these new gene therapy programs to bolster its work on genomic medicine.
September 20, 2023
Under the collaboration, Orionis will receive $47 million upfront to leverage its Allo-Glue platform to discover small-molecule monovalent glues.
CN Bio and LifeNet Health LifeSciences have teamed up to provide direct access to a portfolio of highly characterized hepatic cells for the creation of advanced liver-on-a-chip assays.
September 07, 2023
Illumina’s new solutions center in Bengaluru, India, will expand access to genomics in the country.
Optibrium announced on Aug. 31, 2023 the acquisition of BioPharmics to further expand the 3D drug design and modelling offering and to focus on research and development and application science.
September 05, 2023
Novo Nordisk receives the full rights to develop and commercialize the lead program.
Both companies have a focus to developing and commercializing treatments for rare diseases with a strong focus on patients and supporting communities with little to no existing therapeutic options.
September 03, 2023
Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.
September 02, 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
